Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fostamatinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Fostamatinib. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-004774-97 Sponsor Protocol Number: C-935788-057 Start Date*: 2019-10-23
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    Medical condition: Warm antibody autoimmune hemolytic anemia (wAIHA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Completed) ES (Completed) CZ (Completed) HU (Completed) DK (Completed) DE (Completed) AT (Completed) BE (Completed) NL (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-005454-30 Sponsor Protocol Number: C-935788-049 Start Date*: 2014-11-28
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
    Medical condition: Persistent/Chronic Immune Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10067644 Immune-mediated thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) HU (Completed) CZ (Completed) AT (Completed) NL (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-001882-34 Sponsor Protocol Number: C-935788-058 Start Date*: 2020-01-28
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    Medical condition: Warm antibody autoimmune hemolytic anemia (wAIHA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Prematurely Ended) AT (Prematurely Ended) DK (Completed) FR (Completed) HU (Prematurely Ended) BE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-005452-15 Sponsor Protocol Number: C-935788-047 Start Date*: 2014-09-11
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
    Medical condition: Persistent/Chronic Immune Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10067644 Immune-mediated thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) HU (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-005453-76 Sponsor Protocol Number: C-935788-048 Start Date*: 2014-09-11
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
    Medical condition: Persistent/Chronic Immune Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10067644 Immune-mediated thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000027-14 Sponsor Protocol Number: T-19-11318v19 Start Date*: 2018-08-20
    Sponsor Name:Imperial College London
    Full Title: A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment Chronic Active Antibody Mediated Rejection in Renal Transplantation
    Medical condition: Chronic active antibody mediated rejection of renal transplants
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2020-001750-22 Sponsor Protocol Number: 20HH5926 Start Date*: 2020-07-09
    Sponsor Name:Joint Research Compliance Office
    Full Title: MATIS: Phase 2/3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia
    Medical condition: COVID-19 pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-020892-22 Sponsor Protocol Number: D4300C00005 Start Date*: 2010-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) DE (Completed) SK (Prematurely Ended) HU (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) CZ (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000331-16 Sponsor Protocol Number: C-935788-050 Start Date*: 2014-07-28
    Sponsor Name:Rigel Pharmaceuticals Inc
    Full Title: A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
    Medical condition: IgA nephropathy (IgAN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023692-26 Sponsor Protocol Number: D4300C00004 Start Date*: 2011-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: (OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab M...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000715-31 Sponsor Protocol Number: ACTIV-4 Start Date*: 2022-08-24
    Sponsor Name:NEAT ID
    Full Title: Clinical Trials targeting macro-, micro-immuno-thrombosis, vascular hyperinflammation, and hypercoagulability and renin-angiotensin-aldosterone system (RAAS) in hospitalized patients with COVID-19 ...
    Medical condition: COVID-19 viral infection
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004862 10085775 Laboratory confirmed COVID-19 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006070-73 Sponsor Protocol Number: D4300C00033 Start Date*: 2012-08-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-020744-35 Sponsor Protocol Number: D4300C00002 Start Date*: 2010-10-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Re...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) LV (Completed) LT (Completed) CZ (Completed) PT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020745-27 Sponsor Protocol Number: D4300C00003 Start Date*: 2010-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Respon...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Completed) ES (Completed) FR (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-005371-16 Sponsor Protocol Number: D4302C00001 Start Date*: 2012-07-30
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Medical condition: Diffuse Large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020743-12 Sponsor Protocol Number: D4300C00001 Start Date*: 2010-10-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Res...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) SK (Completed) HU (Completed) EE (Completed) PL (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-000744-13 Sponsor Protocol Number: C-935788-012 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients with Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) FR (Completed) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000742-30 Sponsor Protocol Number: C-935788-010 Start Date*: 2008-10-18
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004032-21 Sponsor Protocol Number: ARGX-113-2004 Start Date*: 2021-05-07
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immu...
    Medical condition: Primary immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10083843 Primary immune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) PT (Completed) DE (Completed) BG (Completed) NO (Completed) DK (Completed) GR (Completed) IT (Completed) FR (Completed) RO (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009034-32 Sponsor Protocol Number: 4/2009 Start Date*: 2009-06-28
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: R788 as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
    Medical condition: Chronic Lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 12:32:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA